**Supplementary Table 1: Adjusted linear regression analysis to assess effect of study enrollment location on door to needle time (min)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Beta | Coefficient | Std Error | 95% CI | | t | p |
| MSU-treated | -0.1 | -17.2 | 3.7 | -24.6 | -9.7 | 4.5 | <0.0001 |
| UAH-Treated | 0.04 | 2.8 | 1.6 | -0.4 | 6 | 1.7 | 0.08 |

MSU, Mobile stroke unit; UAH, University of Alberta; NIHSS, National Institute of Health Stroke Scale; CI, Confidence interval; Non-UAH treated was base category for MSU-and UAH -treated categories; (prespecified variables as potential confounders in the regression model: age, sex, baseline NIHSS, visible occlusion and type of intravenous thrombolysis, male sex was base category for female sex; no visible occlusion was base category for presence of visible occlusion category). (Mean variation inflation factor 1.08)

**Supplementary Table 2: Adjusted linear regression analysis to assess effect of study enrollment location on CT to needle time (min)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Beta | Coefficient | Std Error | 95% CI | | t | p |
| MSU-treated | -0.08 | -10.7 | 3.3 | -17.1 | -4.2 | -3.2 | 0.001 |
| UAH-Treated | 0.05 | 3.1 | 1.4 | 0.4 | 5.9 | 2.2 | 0.03 |

MSU, Mobile stroke unit; UAH, University of Alberta; NIHSS, National Institute of Health Stroke Scale; CI, Confidence interval; Non-UAH treated was base category for MSU-and UAH -treated categories; (prespecified variables as potential confounders in the regression model: age, sex, baseline NIHSS, visible occlusion and type of intravenous thrombolysis, male sex was base category for female sex; no visible occlusion was base category for presence of visible occlusion category). (Mean variation inflation factor 1.08)

**Supplementary Table 3: Adjusted Logistic regression analysis to assess effect of study enrollment location on excellent outcome (modified Rankin scale 0-1) at 90-120 days**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Odd ratio | 95% CI | | Std Error | z | p |
| MSU-treated | 1.7 | 0.9 | 3.2 | 0.6 | 1.6 | 0.1 |
| UAH-Treated | 1 | 0.8 | 1.3 | 0.1 | 0.04 | 0.9 |

MSU, Mobile stroke unit; UAH, University of Alberta; NIHSS, National Institute of Health Stroke Scale; CI, Confidence interval; Non-UAH treated was base category for MSU-and UAH -treated categories; (prespecified variables as potential confounders in the regression model: age, sex, baseline NIHSS, visible occlusion and type of intravenous thrombolysis, male sex was base category for female sex; no visible occlusion was base category for presence of visible occlusion category).

**Supplementary Table 4: Adjusted Logistic regression analysis to assess effect of study enrollment location on good outcome (modified Rankin scale 0-2) at 90-120 days**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Odd ratio | 95% CI | | Std Error | z | p |
| MSU-treated | 1.6 | 0.8 | 3.3 | 0.6 | 1.2 | 0.2 |
| UAH-Treated | 0.9 | 0.7 | 1.3 | 0.1 | -0.4 | 0.7 |

MSU, Mobile stroke unit; UAH, University of Alberta; NIHSS, National Institute of Health Stroke Scale; CI, Confidence interval; Non-UAH treated was base category for MSU-and UAH -treated categories; Male sex was base category for Female sex; No visible occlusion was base category for presence of visible occlusion category.

**Supplementary Table 5: Adjusted Logistic regression analysis to assess effect of study enrollment location on death at 90-120 days**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Odd ratio | 95% CI | | Std Error | z | p |
| MSU-treated | 0.4 | 0.1 | 1.8 | 0.3 | -1.2 | 0.2 |
| UAH-Treated | 1.57 | 1.08 | 2.26 | 0.29 | 2.42 | 0.02 |

MSU, Mobile stroke unit; UAH, University of Alberta; NIHSS, National Institute of Health Stroke Scale; CI, Confidence interval; Non-UAH treated was base category for MSU-and UAH -treated categories; (prespecified variables as potential confounders in the regression model: age, sex, baseline NIHSS, visible occlusion and type of intravenous thrombolysis, male sex was base category for female sex; no visible occlusion was base category for presence of visible occlusion category).